10 results
Primary Objective: the primary objective of this study is to investigate the accuracy and reliability of coronal curve ultrasound measurements in patients with scoliosis as well as the accuracy and reliability of ultrasound imaging to detect…
Parts A and B:To evaluate the efficacy of efgartigimod PH20 SC on achieving sustained remission in the treatment of participants with bullous pemphigoid (BP)
The main goal of the study is to investigate if small amounts of dopamine could influence engagement during reading, comprehension of the story and vocabulary learning and to investigate if the effect of dopamine is different for carriers of the…
The primary objective of this study is to investigate the accuracy and reliability of ultrasound scoliosis measurements and progression of the curve and to correlate these outcomes with the standard radiographic measurements obtained at the same…
Primary Objective:- Efficacy of ARGX-113 as assessed by the percentage of "Myasthenia Gravis Activities of Daily Living (MG-ADL) responders" in the acetylcholine receptor (AChR)- antibody (Ab) seropositive population.Secondary Objectives:1…
The aim of this trial is to investigate the long-term safety, tolerability, and immunogenicity of efgartigimod administered intravenously (IV) in pediatric participants rolling over from the ARGX-113-2006 trial and to ensure access to the drug…
To confirm an age-adjusted optimum dose of efgartigimod IV and provide (model-predicted) evidence for a treatment response.
Primary objective:- To assess the clinical efficacy of efgartigimod IV 10mg/kg administered in a q2w continuous regimen compared to that administered in a cyclic regimen.Secondary objectives:- To evaluate the safety and tolerability of both…
Main objective:- To evaluate the long-term safety and tolerability of ARGX-113 in acetylcholine receptor antibody (AChR-Ab) seropositive patients.Secondary objective:- To evaluate the long-term safety and tolerability of ARGX-113 in the overall…
To assess the long-term safety and tolerability of treatment with efgartigimod PH20 SC in participants with BP